Inactive Instrument

SWK Holdings Corp Stock Other OTC

Equities

US78501P1049

Corporate Financial Services

End-of-day quote Other OTC
- USD - Intraday chart for SWK Holdings Corp
Sales 2024 * 38.9M Sales 2025 * 41.3M Capitalization 217M
Net income 2024 * 23M Net income 2025 * 14M EV / Sales 2024 * 5.57 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 5.25 x
P/E ratio 2024 *
9.38 x
P/E ratio 2025 *
15 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 98.07%
More Fundamentals * Assessed data
Managers TitleAgeSince
Chief Executive Officer 43 15-07-31
Comptroller/Controller/Auditor - 23-06-30
Corporate Officer/Principal - 22-01-31
Members of the board TitleAgeSince
Chairman 63 22-02-08
Director/Board Member 61 22-02-14
Director/Board Member 36 21-05-16
More insiders
SWK Holdings Corporation is engaged in specialty finance and asset management business. The Company’s segments include Finance Receivables and Pharmaceutical Development. Finance Receivables segment is a healthcare capital provider, which offers customized financing solutions to a range of life science companies, institutions, and inventors. This segment is primarily focused on monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Its Pharmaceutical Development segment operates through its subsidiary Enteris BioPharma, Inc. (Enteris). Enteris is a clinical development and manufacturing organization providing development services to pharmaceutical partners as well as innovative formulation solutions built around its oral drug delivery technologies, the Peptelligence platform.
Related indices
More about the company